Intracoronary Reopro during Percutaneous Coronary Intervention in Acute and Stable Patient can Influence Stent Thrombosis Formation (IRPASST) Study

BACKGROUND: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high...

Descripción completa

Detalles Bibliográficos
Autores principales: Balghith, Mohammed, Al-Ghamdi, Ali, Zain, El harif, Al-Saileek, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752878/
https://www.ncbi.nlm.nih.gov/pubmed/23983910
http://dx.doi.org/10.4103/1995-705X.115498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752878/
https://www.ncbi.nlm.nih.gov/pubmed/23983910
http://dx.doi.org/10.4103/1995-705X.115498

Ejemplares similares